These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9886705)

  • 1. From cost of illness to cost-effectiveness in heart failure.
    Lévy E
    Eur Heart J; 1998 Dec; 19 Suppl P():P2-4. PubMed ID: 9886705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness of bisoprolol in chronic heart failure].
    Ekman M; Zethraeus N; Dahlström U; Höglund C
    Lakartidningen; 2002 Feb; 99(7):646-50. PubMed ID: 11887711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland.
    Barry M
    Ir Med J; 2002 Jun; 95(6):174, 176-7. PubMed ID: 12171265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New studies influencing treatment of heart failure: 2006 update.
    Dunlap ME
    Pharmacotherapy; 2007 Apr; 27(4 Pt 2):3S-11S. PubMed ID: 17381369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing readmissions for congestive heart failure.
    Hoyt RE; Bowling LS
    Am Fam Physician; 2001 Apr; 63(8):1593-8. PubMed ID: 11327436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II].
    Lévy P; Mérot JL; Lechat P; Lévy E; Bogillot O
    Therapie; 2001; 56(4):421-5. PubMed ID: 11677866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of beta-blocker treatment in heart failure.
    Gilbert EM
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S42-7. PubMed ID: 12447161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with beta blockers in heart failure mortality trials.
    Eichhorn EJ
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V21-9. PubMed ID: 10526700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D; Unal B; Critchley J; Capewell S
    QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of heart failure treatment.
    Guyatt GH; Devereaux PJ
    Mt Sinai J Med; 2004 Jan; 71(1):47-54. PubMed ID: 14770250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-Blocker therapy in heart failure.
    Doughty RN
    Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic blocking drugs in severe heart failure.
    Fowler M
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S20-6. PubMed ID: 12447158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I; Liu P; Webb G
    Int J Cardiol; 2004 Dec; 97 Suppl 1():25-33. PubMed ID: 15590076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of bisoprolol treatment for heart failure.
    Di Stasi F; Scalone L; De Portu S; Menditto E; Mantovani LG
    Ital Heart J; 2005 Dec; 6(12):950-5. PubMed ID: 16502708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.